Literature DB >> 27827355

Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system.

Nicole L Caspers1, Seungil Han1, Francis Rajamohan1, Lise R Hoth1, Kieran F Geoghegan1, Timothy A Subashi2, Michael L Vazquez3, Neelu Kaila3, Ciarán N Cronin4, Eric Johnson4, Ravi G Kurumbail1.   

Abstract

Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium. The tightly bound Mg2+-ADP at the ATP-binding site proved recalcitrant to ligand displacement. Addition of a molar excess of EDTA helped to dislodge the divalent metal ion, promoting the release of ADP and allowing facile exchange with ATP-competitive small-molecule ligands. Many kinases require the presence of a stabilizing ligand in the ATP site for crystallization. This procedure could be useful for developing co-crystallization systems with an exchangeable ligand to enable structure-based drug design of other protein kinases.

Entities:  

Keywords:  Janus kinase; crystal soaking; kinases; ligand exchange; structure-based drug design

Mesh:

Substances:

Year:  2016        PMID: 27827355      PMCID: PMC5101585          DOI: 10.1107/S2053230X16016356

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  23 in total

1.  A protein tyrosine kinase in the interferon alpha/beta signaling pathway.

Authors:  L Velazquez; M Fellous; G R Stark; S Pellegrini
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

2.  tyk2, prototype of a novel class of non-receptor tyrosine kinase genes.

Authors:  I Firmbach-Kraft; M Byers; T Shows; R Dalla-Favera; J J Krolewski
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

3.  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.

Authors:  Jill E Chrencik; Akshay Patny; Iris K Leung; Brian Korniski; Thomas L Emmons; Troii Hall; Robin A Weinberg; Jennifer A Gormley; Jennifer M Williams; Jacqueline E Day; Jeffrey L Hirsch; James R Kiefer; Joseph W Leone; H David Fischer; Cynthia D Sommers; Horng-Chih Huang; E J Jacobsen; Ruth E Tenbrink; Alfredo G Tomasselli; Timothy E Benson
Journal:  J Mol Biol       Date:  2010-05-15       Impact factor: 5.469

4.  Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Authors:  Janusz J Kulagowski; Wade Blair; Richard J Bull; Christine Chang; Gauri Deshmukh; Hazel J Dyke; Charles Eigenbrot; Nico Ghilardi; Paul Gibbons; Trevor K Harrison; Peter R Hewitt; Marya Liimatta; Christopher A Hurley; Adam Johnson; Tony Johnson; Jane R Kenny; Pawan Bir Kohli; Robert J Maxey; Rohan Mendonca; Kyle Mortara; Jeremy Murray; Raman Narukulla; Steven Shia; Micah Steffek; Savita Ubhayakar; Mark Ultsch; Anne van Abbema; Stuart I Ward; Bohdan Waszkowycz; Mark Zak
Journal:  J Med Chem       Date:  2012-06-11       Impact factor: 7.446

5.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Authors:  Titus J Boggon; Yiqun Li; Paul W Manley; Michael J Eck
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 6.  Jaks and STATs: biological implications.

Authors:  W J Leonard; J J O'Shea
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  FDA approves tofacitinib for rheumatoid arthritis.

Authors:  Kate Traynor
Journal:  Am J Health Syst Pharm       Date:  2012-12-15       Impact factor: 2.637

8.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

Authors:  Isabelle S Lucet; Emmanuelle Fantino; Michelle Styles; Rebecca Bamert; Onisha Patel; Sophie E Broughton; Mark Walter; Christopher J Burns; Herbert Treutlein; Andrew F Wilks; Jamie Rossjohn
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

9.  U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

Authors:  Albert Deisseroth; Edvardas Kaminskas; Joseph Grillo; Wei Chen; Haleh Saber; Hong L Lu; Mark D Rothmann; Satjit Brar; Jian Wang; Christine Garnett; Julie Bullock; Laurie B Burke; Atiqur Rahman; Rajeshwari Sridhara; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-04-27       Impact factor: 12.531

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.

Authors:  Sathya Babu; Santhosh Kumar Nagarajan; Sruthy Sathish; Vir Singh Negi; Honglae Sohn; Thirumurthy Madhavan
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

2.  On the Mechanism of Action of Anti-Inflammatory Activity of Hypericin: An In Silico Study Pointing to the Relevance of Janus Kinases Inhibition.

Authors:  Luca Dellafiora; Gianni Galaverna; Gabriele Cruciani; Chiara Dall'Asta; Renato Bruni
Journal:  Molecules       Date:  2018-11-22       Impact factor: 4.411

3.  The structure-function relationship of oncogenic LMTK3.

Authors:  Angeliki Ditsiou; Chiara Cilibrasi; Nikiana Simigdala; Athanasios Papakyriakou; Leanne Milton-Harris; Viviana Vella; Joanne E Nettleship; Jae Ho Lo; Shivani Soni; Goar Smbatyan; Panagiota Ntavelou; Teresa Gagliano; Maria Chiara Iachini; Sahir Khurshid; Thomas Simon; Lihong Zhou; Storm Hassell-Hart; Philip Carter; Laurence H Pearl; Robin L Owen; Raymond J Owens; S Mark Roe; Naomi E Chayen; Heinz-Josef Lenz; John Spencer; Chrisostomos Prodromou; Apostolos Klinakis; Justin Stebbing; Georgios Giamas
Journal:  Sci Adv       Date:  2020-11-13       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.